Anti-mPD-1-mlgG1e3 InvivoFit[™]

RMP1-14-derived recombinant mouse monoclonal antibody against murine PD-1 Catalog code: mpd1-mab15-1, mpd1-mab15-10, mpd1-mab15-50, mpd1-mab15-100 https://www.invivogen.com/anti-mpd1-migg1e3-invivofit

nttps://www.invivogen.com/anti-mpd1-migg1e3-invivorit

For research use only, not for diagnostic or therapeutic use

Version 22G12-AK

PRODUCT INFORMATION

Contents:

Anti-mPD-1-mlgG1e3 InvivoFit[™], purified monoclonal antibody (mAb), provided azide-free and lyophilized. It is available in four pack sizes:

- 1 mg
- 10 mg
- 50 mg (5 x 10 mg)
- 100 mg (10 x 10 mg)

Target: Murine programmed cell death 1 (mPD-1)

Clone: RMP1-14-derived

Source: Chinese hamster ovary (CHO) cells

Sequence: ~65% murine (constant region) and ~35% rat (variable region) Isotype: Murine IgG1e3 (D265A mutation; no effector function) Light chain type: Kappa

Purification: Affinity chromatography with protein A

Formulation: 0.2 µm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharose **Administration:** Suitable for parenteral delivery in mice

Tested applications: Flow cytometry and ELISA

Antibody resuspension (2 mg/ml)

<u>Note:</u> Ensure you see the lyophilized pellet before resuspension. Resuspend Anti-mPD-1-mlgG1e3 InvivoFit with sterile water:

- Add 500 µl to 1 mg
- Add 5 ml to 10 mg

Storage and stability

- Product is shipped at room temperature. Store lyophilized antibody

- at -20 °C. Lyophilized product is stable for at least 1 year.
- Reconstituted antibody is stable for 1 month d at 4 $^{\circ}\rm C$ and for 1 year at -20 $^{\circ}\rm C.$ Avoid repeated freeze-thaw cycles.

Quality control

- Binding of Anti-mPD-1-mlgG1e3 InvivoFit[™] to mPD-1 has been confirmed using flow cytometry.

- The complete sequence of this antibody has been verified.
- <5% aggregates (confirmed by size exclusion chromatography).

- Anti-mPD1-mlgG1e3 InvivoFit^m is filter-sterilized (0.2 µm) and its endotoxin level is <1 EU/mg (determined by the LAL assay).

BACKGROUND

Programmed cell death 1 (PD-1; also known as CD279) is a type I transmembrane protein expressed at the cell surface of activated and exhausted conventional T cells¹. PD-1 is an inhibitory immune checkpoint that prevents T-cell overstimulation and host damage. PD-1 interaction with its ligands PD-L1 (programmed cell death ligand 1) or PD-L2 induces inhibition of T-cell receptor signaling¹. Blockade of PD-1 with mAbs has allowed unprecedented remissions in patients with metastatic melanoma or non-small cell lung cancer¹.


TECHNICAL SUPPORT InvivoGen USA (Toll-Free): 888-457-5873 InvivoGen USA (International): +1 (858) 457-5873 InvivoGen Europe: +33 (0) 5-62-71-69-39 InvivoGen Hong Kong: +852 3622-3480 E-mail: info@invivogen.com

DESCRIPTION

Anti-mPD-1-mlgG1e3 InvivoFit[™] is a recombinant mAb designed for *in vivo* studies in mice. It features the variable region of the previously described anti-mPD-1 RMP1-14 mAb² and the engineered murine lgG1e3 constant region. The RMP1-14 mAb targets and blocks mPD-1 antigen². However, the RMP1-14 mAb, along with other commercially available anti-mPD-1 mAbs, were generated in rats, and are therefore immunogenic in mice. Additionally, these mAbs feature the IgG2a isotype which promotes antibody-dependent cellular cytotoxicity. To overcome these two issues, InvivoGen offers a mouse anti-mouse mAb (non-immunogenic) featuring an isotype devoid of effector function.

Anti-mPD-1-mIgG1e3 InvivoFit[™] was generated by recombinant DNA technology so that it is ~65% murine (constant region) and with a point mutation D265A (a replacement of aspartic acid by alanine at position 265), resulting in the complete loss of cytolytic effector function^{2.3}. Anti-mPD-1-mIgG1e3 InvivoFit[™] is thus ideal for blocking the mPD-1 receptor without causing T cell depletion.

This antibody is produced in CHO cells and purified by affinity chromatography with protein A.



InvivoGen's engineered Anti-mPD-1-mIgG1e3 InvivoFit[™] antibody.

1. Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55. 2. Yamazaki T. *et al.*, 2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92. 3. Baudino L. *et al.*, 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol. 181(9):6664-9.

RELATED PRODUCTS

Product

Catalog Code

Anti-hPD1-Pem-hlgG4 (S228P) (Pembrolizumab) Anti-hPD1-Ni-hlgG4 (S228P) (Nivolumab) Anti-mCTLA4-mlgG2a InvivoFit™ Anti-PD-L1-mlgG1 InvivoFit™ Raji-hPD-1 Cells hpd1pe-mab14 hpd1ni-mab114 mctla4-mab10-1 pdl1-mab9-1 raji-hpd1

Other antibody isotype families are available, such as Anti-hCD20 and Anti-HER2. For more information visit <u>https://www.invivogen.com/antibody-isotypes</u>.

